Vanitha Sampath

TL;DR: The phase 2a results suggest etokimab is safe and well tolerated and that a single dose of etokIMab could have the potential to desensitize peanut-allergic participants and possibly reduce atopy-related adverse events.

TL;DR: Allergists and other healthcare providers in the field of allergies and associated airway diseases are on the front line, taking care of patients potentially infected with SARS‐CoV‐2, so strategies and practices to minimize risks of infection have to be developed and followed.

TL;DR: In this paper, the authors evaluated 60 multifood-allergic patients by measuring serum IgE to key allergen components, evaluating clinical histories and medication use, performing skin tests, and conducting double-blind, placebo-controlled food challenges.

TL;DR: In this article, the authors provide an overview of different types of allergic adverse reactions that can potentially occur after vaccination and individual vaccine components capable of causing the allergic adverse reaction and their implications for individual diagnosis and management and vaccine manufacturing overall.

TL;DR: The increasing prevalence of FA, lack of robust biomarkers, and inadequate treatments warrants further research into the mechanism underlying food allergies, and parallel advances in bioinformatics and computational techniques have enabled the integration, analysis, and interpretation of exponentially growing data sets.